Associated Genetic Biomarkers
SDC1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains SDC1 status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with SDC1 status in the inclusion eligibility criteria most commonly target multiple myeloma .
The most frequent alteration to serve as an inclusion eligibility criterion is SDC1 Expression .
Bcma-specific car-modified t-cell therapy, crenigacestat, cyclophosphamide, and fludarabine are the most frequent therapies in trials with SDC1 as an inclusion criteria .
Significance of SDC1 in Diseases
Multiple Myeloma +
SDC1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains SDC1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.